Apellis Pharmaceuticals, Inc. (DELISTED) (APLS:DL)
41.03
0.00 (0.00%)
USD |
NASDAQ |
May 22, 16:00
Apellis Pharmaceuticals Cash from Investing (Quarterly) : 0.00 for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -209.50M |
| Eli Lilly & Co. | -3.916B |
| Agios Pharmaceuticals, Inc. | 141.31M |
| Spyre Therapeutics, Inc. | 56.58M |
| Scholar Rock Holding Corp. | -5.335M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -60.97M |
| Cash from Financing (Quarterly) | 0.064M |
| Free Cash Flow | 37.47M |
| Free Cash Flow Per Share (Quarterly) | -0.4639 |
| Free Cash Flow to Equity (Quarterly) | -62.36M |
| Free Cash Flow to Firm (Quarterly) | -50.92M |
| Free Cash Flow Yield | 0.71% |